Fate Therapeutics's Total Assets for the quarter that ended in Sep. 2024 was $494.97 Mil.
Warning Sign:
If a company builds assets at 68.3% a year, faster than its revenue growth rate of 58.7% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Fate Therapeutics's average Total Assets Growth Rate was 2.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 11.00% per year.
During the past 5 years, the average Total Assets Growth Rate was 68.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 85.40% per year.
During the past 13 years, Fate Therapeutics's highest 3-Year average Total Assets Growth Rate was 217.90%. The lowest was 11.00%. And the median was 38.60%.
The historical data trend for Fate Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Fate Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fate Therapeutics (NAS:FATE) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Sep. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Fate Therapeutics's Asset Turnover for the quarter that ended in Sep. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Fate Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Fate Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FATE has been successfully added to your 